The Latest Breaking News from Gene Therapy

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193  in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Without treatment she now has just three to six months to live, doctors say

London nursery manager Maria Barry, 58, was horrified to discover truth behind chronic symptom

McCarthy, 37, worked at a gene therapy startup and graduated from DePaul University; he died alongside his wife, Irina.

Sarepta is building a base as this biotech stock tries to convince regulators to approve its gene therapy.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy.  SRP-9001 is an investigational gene therapy under development in partnership with Roche Holdings AG (OTC:RHHBY).  Results from Cohort 1 demonstrated a 3.8-point improvement and 3.2-point improvement on the Duchenne functional scale 52 weeks after…

Precigen Inc (NASDAQ:PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal consideration includes $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023. …

Gene therapy and gene editing get all the glory, but investors shouldn't overlook an emerging group of tools.

Oyster Point Pharma Inc (NASDAQ:OYST) will implement an operating expense streamlining plan to reduce employee and non-employee expenses (up to 50 roles) across the organization.  The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 field-based sales resources. The plan is expected to reduce operating expenses by approximately $6…